Monoclonal antibodies (mAbs) may directly stall or kill tumour cells by binding tumour cell-specific antigens, or indirectly kill tumour cells by inhibiting the immune checkpoint molecules that ...
"Artificial intelligence promises a turning point in antibody drug discovery ... the binding epitopes on target antigens using 3D structural models and docking-based methodologies.